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Abstract
As part of the European research consortium IBDase, we addressed the role of proteases and protease inhibitors (P/PIs) in
inflammatory bowel disease (IBD), characterized by chronic mucosal inflammation of the gastrointestinal tract, which affects
2.2 million people in Europe and 1.4 million people in North America. We systematically reviewed all published genetic
studies on populations of European ancestry (67 studies on Crohn’s disease [CD] and 37 studies on ulcerative colitis [UC]) to
identify critical genomic regions associated with IBD. We developed a computer algorithm to map the 807 P/PI genes with
exact genomic locations listed in the MEROPS database of peptidases onto these critical regions and to rank P/PI genes
according to the accumulated evidence for their association with CD and UC. 82 P/PI genes (75 coding for proteases and 7
coding for protease inhibitors) were retained for CD based on the accumulated evidence. The cylindromatosis/turban tumor
syndrome gene (CYLD) on chromosome 16 ranked highest, followed by acylaminoacyl-peptidase (APEH), dystroglycan
(DAG1), macrophage-stimulating protein (MST1) and ubiquitin-specific peptidase 4 (USP4), all located on chromosome 3. For
UC, 18 P/PI genes were retained (14 proteases and 4protease inhibitors), with a considerably lower amount of accumulated
evidence. The ranking of P/PI genes as established in this systematic review is currently used to guide validation studies of
candidate P/PI genes, and their functional characterization in interdisciplinary mechanistic studies in vitro and in vivo as part
of IBDase. The approach used here overcomes some of the problems encountered when subjectively selecting genes for
further evaluation and could be applied to any complex disease and gene family.
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Introduction
About 2.2 million people in Europe and 1.4 million people in
North America suffer from inflammatory bowel disease (IBD),
characterized by chronic mucosal inflammation of the gastroin-
testinal tract. It is a lifelong disease affecting mostly young to
middle aged people of 15–40 years, in a chronic and often severe
way. The prevalence has increased steadily since the 1950s and is
currently estimated at 0.2 to 0.3% [1,2]. Two main phenotypes
are distinguished, Crohn’s disease (CD) and ulcerative colitis (UC),
both with distinct histopathological features and clinical manifes-
tations [3]. The cause of IBD is multifactorial - environmental and
genetic - and poorly understood [4].
The genetic background of CD has been extensively evaluated.
Since the late 1990s, a heterogeneous body of evidence on the genetics
of CD has been collected by many research groups using different
study designs in different settings and countries across the world. This
led to significant insights into the mechanism of the disease, such as a
disturbed surveillance of bacteria of the microflora by the intestinal
mucosa (CARD15) [5,6], dysregulation of adaptive immunity (IL23R)
[7], or deficient autophagy (ATG16L1, IRGM) [8,9].
The selection of genes of interest in a susceptibility region is
based on subjective interpretation of external evidence, or on
theoretical considerations of potential mechanisms of disease. To
overcome subjective selection of candidate genes, genomic
locations of genes of interest could be systematically mapped onto
susceptibility regions found to be linked to or associated with IBD
(‘‘critical regions’’). Genes could then be ranked according to the
accumulating evidence on their association with IBD in different
study types while avoiding subjective judgment.
Proteases and protease inhibitors (P/PIs) are involved in
mechanisms contributing to the mucosal barrier function of the
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gut and may therefore be important in IBD. The Inflammatory
Bowel Disease protease (IBDase) project is a collaborative project
of nine academic groups across Europe funded by the European
Framework Programme 7, which aims at identifying novel
therapeutic targets among P/PIs. During the first stage of IBDase
described here, we systematically reviewed all published genetic
linkage and association studies in populations of European
ancestry to identify critical genomic regions associated with IBD.
We proceeded as described above to systematically map all known
P/PI genes listed in MEROPS, a comprehensive database of
peptidases [10], onto these critical regions using a computer
algorithm and ranked P/PI genes according to accumulated
evidence for association of P/PI genes with IBD.
Results
Figure 1 presents the flow of information through the different
phases of the systematic review of genetic studies on inflammatory
bowel disease in populations of European ancestry. The PubMed
search resulted in 1504 hits, screening of reference lists of included
papers and relevant reviews yielded an extra 79 records. We
excluded 1389 articles based on information provided in title and
abstract, retrieved the full texts of 204 reports, and eventually
included 61 published reports and 4 unpublished reports, which
were published after completion of the literature search as
full journal articles [11–14]. These reports described 84 unique
studies in the systematic review: 7 genome-wide association scans
(GWAS) [8,11,12,15–18], 9 replications of GWAS [9,11–14,16,19],
20 candidate gene studies [8,20–31], 36 candidate region
studies [11,17,18,32–66], and 12 genome-wide linkage scans
[38,42,44,49,54,59,61,67–72]. 67 studies were on CD, 37 on UC.
5 GWAS, 4 replications of GWAS, 16 candidate gene studies, 31
candidate region studies, and 11 genome-wide linkage scans studied
patients with CD; 2 GWAS, 6 replications of GWAS, 8 candidate
gene studies, 16 candidate region studies, and 5 genome-wide
linkage scans studied patients with UC. Critical genomic regions
associated with IBD were defined on the basis of the information
provided in these studies, considering the HapMap of the CEU
population (for further details see www.hapmap.org and methods).
38 studies that reported on patients with inflammatory bowel
disease without distinction of CD and UC, and 11 studies on
‘‘mixed’’ families (with members affected with UC or CD), were
disregarded. Table S1 presents the design and the methodological
quality of included studies. 70 studies were classified to have
adequate protection against bias in phenotype definition (83%), 52
against bias in genotyping (62%) and 66 against the effects of
population stratification (79%).
807 out of 1111 entries on P/PI genes in MEROPS had
information on exact genomic locations available and were
included (Table S2). Figure 2 presents the number of positive
studies per P/PI gene (left), the percentage of positive studies per
P/PI gene (middle), and the distribution of evidence scores (right)
for both, CD (top) and UC (bottom). The maximum evidence
score, the pre-specified primary outcome, was 1142 for CD and
363 for UC. In CD, 770 P/PI genes had evidence scores of less
than 50; for 607 genes, less than 2 studies were positive. In UC, the
corresponding numbers were 801 and 779. The p-value for the
observed versus expected distribution of scores for associations of
P/PIs with Crohn’s disease was at 2.32270, whereas the
corresponding p-value for UC was 1.47242.
Figure 1. Flow diagram of the systematic review.
doi:10.1371/journal.pone.0024106.g001
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Top ranked P/PI genes in Crohn’s disease
82 P/PI genes (75 coding for proteases and 7 coding for
protease inhibitors) satisfied the threshold criteria for retention of
at least 2 positive studies and evidence scores .50 and are
presented in Table S3. Figure 2A presents the number of positive
studies per P/PI gene (left), the percentage of positive studies per
P/PI gene (middle), and the distribution of evidence scores. The
largest number of positive studies was 21 (1 gene), followed by 11
(1 gene), 9 (6 genes), 8 (4 genes), 7 (3 genes), 6 (1 gene), 5 (14
genes), 4 (16 genes), 3 (43 genes), and 2 (111 genes; Figure 2A).
The 20 highest ranked genes all had evidence scores .200
(Table 1). Figure 3A presents the chromosomal location of top-
ranked P/PI genes in Crohn’s disease: 13 out of the 20 genes were
located on chromosome 16 (65%), 4 on chromosome 3 (20%), 2 on
chromosome 19 (10%) and one on chromosome 2 (5%). Figure S1
provides more detailed information in a chromosome plot of the
number of studies covering different genomic regions and the
corresponding number of positive studies. Figure 4 presents results
for the highest ranked P/PI gene, the cylindromatosis/turban
tumor syndrome gene (CYLD) located on chromosome 16 (49.33 to
49.39 mega base pairs [Mb]), with a score of 1142 and 21 positive
studies. The figure shows the width of the critical regions in 21
positive studies. CYLD encodes a cytoplasmic deubiquitinating
enzyme interacting with cytoskeletal components and is expressed
in a wide range of different tissues including the intestine. It acts as
a tumor suppressor gene. Mutations, which result in a loss of
function of CYLD, are the cause of benign tumors of skin
appendages [73–75]. CYLD was followed by the acylaminoacyl-
peptidase (APEH, chromosome 3, 49.69 Mb to 49.70 Mb),
dystroglycan (DAG1, chromosome 3, 49.48 Mb to 49.55 Mb),
macrophage-stimulating protein (MST1, chromosome 3,
49.69 Mb to 49.70 Mb) and ubiquitin-specific peptidase 4
(USP4, chromosome 3, 49.29 to 49.35 Mb) which shared the
second rank with a score of 398, and 8 positive studies. The
peroxisomal Lon peptidase (LONP2), located on chromosome 16
(46.84 to 46.94 Mb) ranked sixth with a score of 283 and 11
positive studies. From the group of matrix metalloproteases there
are matrix metalloprotease-2 (MMP2) and membrane-type matrix
protease-2 (MMP15), ranked 12 and 16, respectively.
Top ranked P/PI genes in ulcerative colitis
18 P/PI genes satisfied criteria for retention (14 proteases and 4
protease inhibitors, Table 2). Evidence scores for retained P/PI
genes tended to be lower in UC than in CD. The highest number
of positive studies was 5 (2 genes), followed by 4 (2 genes), 3 (3
genes) and 2 (11 genes; Figure 2B). None of these genes had been
examined in candidate gene studies. 8 out of the 18 genes were
located on chromosome 12 (44%), 5 on chromosome 3 (28%), 2 on
chromosome 6 (11%) and one each on chromosomes 2, 15 and 19
(Figure 3B). Figure S1 provides more detailed information. The
top 5 P/PI genes were all located on chromosome 3 within a
region of 0.6 Mb: acylaminoacyl-peptidase (APEH, 49.69–
49.70 Mb), dystroglycan (DAG1, 49.48–49.55 Mb), macrophage-
stimulating protein (MST1, 49.69 0–49.70 Mb), ubiquitin-specific
peptidase 4 (USP4, 49.29–49.35 Mb) and ubiquitin-specific
peptidase 19 (USP19, 49.12–49.13 Mb). Four of these, APEH,
DAG1, MST1 and USP4, also ranked high for CD (Table 1). 8
among the 18 retained genes are linked to the ubiquitin-
proteasome system (UPS): USP4 on rank 3, USP19 on rank 5,
ubiquitin-specific peptidase 15 on rank 7 (USP 15, chromosome
12, 60.94–61.09 Mb), proteasome catalytic subunits 1i and 3i, and
ubiquitin-specific peptidase 3, 5 and 39 on rank 8 (PSMB9,
chromosome 6, 32.92–32.96 Mb; PSMB8, chromosome 6, 32.91–
32.92 Mb; USP3, chromosome 15, 61.58–61.67 Mb; USP5,
chromosome 12, 6.83–6.85 Mb; USP39, chr. 2, 85.70–
85.73 Mb). Main functions of the UPS are the intracellular
degradation of unneeded, damaged or toxic proteins and an
involvement in antigen presentation.
Figure 2. Histograms on the number of positive studies per P/PI gene (left), the percentage of positive studies per P/PI gene
(middle), and the distribution of evidence scores (right) for Crohn’s disease (A) and ulcerative colitis (B).
doi:10.1371/journal.pone.0024106.g002
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Validation
In CD, all positive controls ranked among the top ranked P/PI
genes. The observed evidence score for the positive control CARD15 in
CD was 1142 and 21 studies were positive. IL23R had a score of 430
and 7 positive studies, whereas ATG16L1 had a score of 380 and 5
positive studies. In UC, IL23R had a score of 457 and 6 positive studies
and would have ranked highest. The CD specific CARD15 did not
reach the pre-specified cut-off for UC, with a score of 29, and 2 positive
studies. Similarly, no evidence was found for ATG16L1 in UC. Figure
S2 presents a plot of original ranks of P/PI genes against ranks yielded
after omission of GWAS in a sensitivity analysis for CD (Panel A) and
UC (Panel B). Results were robust for CD, but showed some changes
for UC at higher ranks. All positive controls again ranked among the
top ranked P/PI genes. Figure S3 presents a plot of original ranks of P/
Figure 3. Chromosomal location of top-ranked P/PI genes in Crohn’s disease (A) and ulcerative colitis (B). (A) The top 20 P/PI genes for
Crohn’s disease clustered on chromosomes 2 (1/20; 5%), 3 (4/20; 20%), 16 (13/20; 65%), and 19 (2/20; 10%). (B) The top 18 P/PI genes for ulcerative
colitis were located on chromosomes 2 (1/18; 6%), 3 (5/18; 28%), 6 (2/18; 11%), 12 (8/18; 44%), 15 (1/18; 6%), and 19 (1/18; 6%). The depicted
chromosomal banding pattern is according to Ensembl (http://Mar2010.archive.ensembl.org/Homo_sapiens/Location/View?) and has been released
by the International System for Human Cytogenetic Nomenclature in 2005.
doi:10.1371/journal.pone.0024106.g003
Proteases and Their Inhibitors in IBD
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PI genes against ranks yielded after use of an alternate weighting
scheme in a second sensitivity analysis for CD (Panel A) and UC (Panel
B). Results were again robust for CD, but showed some changes for
UC at higher ranks. Table S4 shows that 6 out of the 20 top ranked P/
PI genes in CD (30%), located on chromosomes 2, 3 and 16, formally
met criteria of genome-wide significance in the most recent meta-
analysis of GWAS in CD [76], and Table S5 indicates that 7 out of the
18 top ranked P/PI genes in UC (39%), located on chromosomes 3
and 6, formally met criteria of genome-wide significance in the most
recent meta-analysis of GWAS in UC [77]. For CD, mean evidence
scores were 14 (SD 43) for negative controls and 96 (SD 180) for P/PI
genes detected in at least one GWAS (difference282, 95% confidence
interval299 to265, p,0.001). For UC, mean evidence scores were 3
(SD 9) for negative controls and 166 (SD 143) for P/PI genes detected
in at least one GWAS (difference 2163, 95% confidence interval
2174 to 2152, p,0.001).
Discussion
In this systematic review, computer algorithms were used to
map all P/PI genes listed in the MEROPS database onto critical
genomic regions extracted from genetic association and linkage
studies performed in IBD. While the top ranked genes (Table 1
and Table 2) included some P/PIs previously found to be
associated with CD and/or UC, such as MMP2, MMP15 and
MST1, a series of P/PI genes were identified, which have not been
previously related to Crohn’s disease or ulcerative colitis. The top
5 ranked P/PI genes for CD and UC were all characterized by
high evidence scores and positive results in several GWAS and/or
replication studies of GWAS. P/PI genes ranked lower were
typically based on positive results in candidate region studies and
genome-wide linkage scans, which were of lower resolution. At the
time of the last update of our systematic review, most of the
evidence had accumulated for CD, with 67 studies addressing CD
as compared to 37 studies in UC. The number of positive studies
among top ranked P/PIs was considerably larger, evidence scores
were clearly higher and their variation more pronounced in CD as
compared with UC. Unsurprisingly, ranks were completely robust
for CD in a sensitivity analysis omitting GWAS, but showed some
changes in the ranking for UC.
Among the top-ranked P/PIs identified in our study, some of
the most promising are CYLD for CD, and APEH, DAG1 and the
Figure 4. Visual display of results found in 21 positive studies of the top-ranked gene in Crohn’s disease, CYLD. As a illustrative
example for all P/PI genes, the CYLD (cylindromatosis/turban tumor syndrome, chr16q12.1, 49.33–49.39 Mb) gene is shown. CYLD was mapped onto
the critical regions shaded in grey. The critical regions of later studies, including genome-wide association scans and replications of genome-wide
association scans and some candidate region studies, were more narrow compared with critical regions of earlier studies because of the improved
resolution of more recent genotyping platforms.
doi:10.1371/journal.pone.0024106.g004
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group of ubiquitin-specific peptidases for both, CD and UC. In an
expression microarray study, CYLD, encoding a deubiquitinating
enzyme (also see above), has been identified as one of the most
significantly downregulated genes in the intestine of IBD patients
[78]. In an IBD animal model, cyld2/2 mice displayed more severe
intestinal inflammation and intestinal tumorigenesis [79]. APEH
encodes acylpeptide hydrolase, an enzyme expressed in the
intestinal mucosa, which is able to cleave N-formyl peptides
derived from bacteria, a potent pro-inflammatory chemo-attrac-
tant for phagocytes [80]. DAG1 encodes alpha- und beta-
dystroglycan proteins, which are generated from a common
precursor through autocatalytic cleavage. It has been hypothesized
that alpha-dystroglycan acts as a receptor for mycobacterium avium
paraturbeculosis in the intestine, a bacterium repeatedly suspected to
be causally related to CD [81,82]. The ubiquitin-proteasome
system (UPS) is closely linked to the top ranked CYLD and
includes, among the top 20 ranked genes, USP40 for CD, USP3,
USP5, USP15, USP19, USP39, PSMB8, and PSMB9 for UC, and
USP4 for both phenotypes. It is known to play a role in the
development of inflammatory and autoimmune diseases through
multiple pathways, including MHC-mediated antigen presenta-
tion, cytokine and cell cycle regulation, and apoptosis [83]. Finally,
MST1, already repeatedly associated with IBD [11,84,85], was
also ranked high for both CD and UC. It encodes macrophage
stimulating protein 1 and is involved in apoptosis. Note however
that the protein is presumably not active as a protease due to a
mutation at the catalytic site.
In this systematic review we included genetic studies with
differences in methodology (linkage versus association) and thus
differences in resolution and accuracy by which a given genomic
region was studied, in genetic markers used, and in definitions
applied to establish and report association or linkage of a gene or
region with IBD. A formal meta-analysis was not feasible,
therefore. Rather, we based our systematic review on an approach
commonly referred to as vote count [86], and merely distinguished
between positive and negative studies on a specific P/PI gene as
identified by our mapping algorithm. The higher the power of the
studies included in the systematic review the more appropriate
vote count methods will be [87]. As suggested by Barrett et al.
[14], individual genetic studies in IBD often have enough power to
detect large effect sizes, but limited power to detect small to
moderate effects corresponding to odds ratios of 1.2 to 1.5. It is
therefore likely that some of the vote counts observed in included
studies were false negative on small to moderate associations of a
P/PI gene with IBD. We took this into account by using low cut-
offs for evidence scores of P/PI genes to be retained in the final
ranking. This low cut-off counteracted the limited power of
individual genetic studies and was deemed to decrease the overall
risk of false negative conclusions about the association of a P/PI
gene with CD or UC in our review. This means that a P/PI gene
was retained even if the proportion of positive studies was small. If
the majority of negative studies were true negatives and the
majority of positive studies false positives, we would erroneously
suggest an association of a retained P/PI gene with IBD. There
will always be a trade-off between false negatives and false
positives, and our strategy of counteracting false negatives was
bound to increase the risk of false positives. Therefore, any of the
retained P/PI genes considered for further scientific investigation
needs to be confirmed first in an adequately powered, independent
replication study on its association with CD or UC.
We emphasize that even if associations between a P/PI gene
and IBD were true, this does not necessarily indicate that a
polymorphism in this gene has a causal role for CD or UC.
Genetic linkages and associations are influenced by linkage
disequilibrium patterns of the study population, which limit the
resolution of any genetic study. Therefore, associations observed in
our study may not be attributable to single genes but rather to
genomic regions containing several genes, which are in strong
linkage disequilibrium. Therefore, genes other than the P/PI gene
identified by our algorithm in a specific critical region could be
responsible for the observed association with IBD. For example,
the top-ranked P/PI gene in CD, CYLD on chromosome 16 (49.33
to 49.39 Mb) is located adjacent to CARD15 (Mb 49.28 to 49.32)
which traces back to the same critical region. The functional link
of CARD15 to IBD has been firmly and reproducibly established
[5,88,89]: there are several well-characterized polymorphisms in
CARD15 that lead to different capacities of the protein products to
regulate NF-kappaB-mediated inflammatory responses to bacterial
components in the gut, thus providing a causal explanation for the
observed association with the disease. However, the association
and linkage signals of the involved critical region on chromosome
16 can only partially be explained by polymorphisms in CARD15:
Hampe et al. found that a robust association signal in this region
remains after stratification by CARD15 polymorphisms [46]. It is
therefore plausible that an adjacent gene, such as CYLD, may
account for this association signal in this critical region and the
neighborhood of CYLD to CARD15 should not preclude CYLD to
be considered as a potential candidate P/PI gene and further
investigated in IBD. Conditional genotypic analysis of CYLD in
CARD15-negative patients, which is ongoing in the replication
study, will clarify the hypothesized independent association signals
in both genes.
Another important limitation is that we were unable to gauge
the direction of associations between P/PI genes and IBD for two
reasons. First, in the presence of identical genetic markers and
definitions of associations, the vote count used in our study could
not distinguish between an increase in the odds of IBD associated
with the marker in one study and a decrease in the odds associated
with the marker in another study. If both studies were positive on
an association of this marker with IBD, then we would consider
them to be concordant even though they may have found opposite
directions of associations. Second, the heterogeneity in markers
used in different studies makes it impossible to achieve
comparability of measures of association. Even if two studies
showed an association in the same direction and of a similar
magnitude, differences in the types of genetic markers could still
mean that the two studies are actually discordant. Ignoring the
directions of associations as described here, may therefore result in
an overestimation of the accumulated evidence and we emphasize
once more the need for validation of our results. Although being
careful in avoiding any duplicate extraction within the same
genetic region of the same population, we cannot not fully exclude
that some genetic region of some patients were included multiple
times in our study if some previously studied patients were
subsequently included in later studies of larger populations.
Finally, candidate gene and candidate region studies may be
subject to selective reporting and publication bias, with predom-
inant reporting of statistically significant results. We cannot
exclude that this has influenced our ranking of some P/PI genes.
We believe, however, that the direction and magnitude of this bias
are similar across all P/PI genes. Therefore its overall impact on
relative rankings is likely to be small. In addition, a variety of
strategies for internal validation through negative and positive
controls suggested our approach to be valid.
Our method is complementary to the classical approach of
formal meta-analysis: using the algorithm, genetic evidence can be
gauged genome-widely, considering all available studies of
different types, even if different analytical methods were used.
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The common concept ascertained is the ‘critical genomic region’
irrespective of study design and genotyping technique used. This
avoids the need for fully compatible genetic markers or
imputations to achieve compatibility, as used in classical meta-
analysis [14,76,77,90]. The ranking algorithm is based on
numerical information about the critical regions and the genomic
locations of P/PI genes in the human genome in relevant
databases. Errors in these databases inevitably lead to errors in
the gene ranking, which can only be addressed in subsequent
updates. It must be noted that many entries in MEROPS are
putative P/PI genes predicted theoretically, but have not been
functionally validated. For example, Haptoglobin (HP) and
Haptoglobin-related protein (HRP), which rank in the top 20 for
UC (Table 2), are taken up in the MEROPS database due to a
peptidase inhibitor sequence motif, despite that there is no
supporting experimental evidence. The high scores for the firmly
established susceptibility genes CARD15, ATG16L1 and IL23R in
CD, and IL23R in both CD and UC, which were generated by the
algorithm after mapping the genomic locations of these genes onto
the critical regions extracted from genetic studies, suggest that the
methodology used in our systematic review is indeed valid. The
scores for CARD15, ATG16L1 and IL23R in CD, and IL23R in
UC, were in the range of the 20 top-ranked P/PI genes in both
phenotypes.
After closure of our database, various genome-wide association
scans in UC and CD were published [76,77,91–94]. Several
previously known genomic regions were replicated and novel
susceptibility regions were revealed. These studies, together with
other recently published genetic studies [95–100], increase
considerably the available genetic information for UC and CD,
and will be considered in future updates. In an attempt to validate
our approach, however, we examined whether top ranked P/PI
genes met genome-wide significance at the level of p,561028 in
the two most recent meta-analyses of GWAS in CD and UC
[76,77]. For both conditions, the 5 highest ranked P/PI genes all
met genome-wide significance (Table S4 and Table S5). For 14 of
the top 20 P/PI genes in CD and 11 of the top 18 P/PI genes in
UC, criteria of genome-wide significance were not formally met in
the meta-analyses [76,77]. The relevant, but only partial
concordance in 30 to 40% of P/PI genes suggests in any case
that our approach is not redundant in the presence of large scale
meta-analyses. Rather, it will provide complementary information
to be subsequently verified. Based on published results, we are
currently unable to determine whether the discordance observed
was due to false negatives in the meta-analyses or false positives in
our study and would welcome detailed data on all top ranked P/PI
genes as found in these meta-analyses [76,77]. As part of the EC-
funded research project IBDase, the ranking of P/PI genes
established in our systematic review is also used to guide
replication studies of candidate P/PI genes and their functional
characterization in interdisciplinary mechanistic studies in vitro
and in vivo. These additional data will contribute to our
understanding of putative causal links of these genes with IBD.
Methods
P/PI gene table
We used the MEROPS database, release 8.2 (August 2008)
(http://merops.sanger.ac.uk) [10], which includes 694 known
human protease genes and 163 protease inhibitor genes, to identify
all known human P/PI genes. All entries were used, including
hypothetical genes predicted by automatic algorithms. If exact
megabase locations were unavailable in MEROPS, we obtained
exact locations from the Ensembl Genome Browser [101] and the
Entrez Gene database [102]. All locations referred to the National
Center for Biotechnology Information (NCBI) 36 assembly of the
human genome updated November 2005. In case of discrepancies,
the genome draft of the Human Genome Organisation took
precedence over Celera. If only chromosome numbers or
information on cytobands was provided for a P/PI gene and
accurate information on genomic location was lacking, the gene
was dropped.
Literature search and selection of reports
We proceeded according to a binding protocol, accessible online
to members of the research consortium (www.ibdase.org). We
searched PubMed to identify all relevant reports published until
and including June 2008 using the search string (‘‘Inflammatory
Bowel Diseases’’ [Mesh] OR ‘‘Crohn Disease’’ [Mesh] OR
‘‘Colitis, Ulcerative’’ [Mesh]) AND (genome-wide association
stud* [title, abstract] OR genome-wide scan* [title, abstract] OR
genome scan* [title, abstract] OR genetic linkage [title, abstract]
OR mutation* [title, abstract] OR polymorphism* [title, abstract]
OR ‘‘genetic predisposition to disease’’ [MeSH]). In addition, we
checked reference lists of retrieved reports, relevant narrative
reviews [89,103–106] and meta-analyses [14,90]. We included
genome-wide association scans (GWAS), replications of GWAS,
candidate gene studies, candidate region association studies,
candidate region linkage studies, and genome-wide linkage scans
in patients with CD or UC, and controls of Caucasian origin. All
GWAS, replication studies, candidate region studies and genome-
wide linkage scans were included, irrespective of whether they had
specifically reported on a P/PI gene. Candidate gene studies were
included if they had studied at least one of the P/PI genes listed in
MEROPS [10]. One report could include multiple studies, for
example both a GWAS and a replication of this GWAS in a
different population. These were then considered as separate
studies. If multiple reports referred to the same study, we used all
reports for data extraction while carefully avoiding any duplicate
extraction within the same genetic region of the same population.
If multiple study types were performed in the same population (for
example both a GWAS and a candidate gene study), we typically
considered all types since genomic locations and resolutions were
different between types. Studies reported only as abstracts were
excluded. Two reviewers evaluated independently reports for
eligibility. Disagreements were resolved by discussion.
Data extraction
Data were extracted by one out of three investigators (IC, GEB
or EK) and checked by a second investigator. Disagreements were
resolved by discussion. We extracted the measures of linkage or
association with IBD as reported by the authors, the correspond-
ing 95% confidence interval and p-values. We used the criteria
specified by the authors to distinguish between statistically positive
and negative results. If the authors did not specify a cut-off, we
used the criteria by Lander and Kruglyak for linkage studies [107]
and p,561027 for significance in GWAS [108].
For candidate gene studies, the critical region was defined as the
genomic location of the studied genes. This exact location was
obtained from MEROPS [10], Ensembl [101] or Entrez Gene
database [102] as described above. For all other study types, we
referred to critical regions as defined by the authors. If information
on the exact region of linkage or association was unavailable, the
critical region was defined depending on the type of study. In
candidate region linkage studies, we used information given on the
used microsatellite markers to establish the boundaries of the
critical region. These boundaries were considered to be located
one score unit upstream and one unit downstream from the peak
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non-parametric linkage (NPL) or logarithm of odds (LOD) score. If
the markers and/or NPL/LOD-scores were not provided in text
or tables, we extracted the information from published graphs. For
whole-genome linkage scans, the same approach was used, with
the extension of defining the critical region to extend one average
distance between two markers upstream and downstream if no
information on NPL/LOD scores was available. For candidate
region association studies using single nucleotide polymorphisms
(SNPs), critical regions were defined by the position of the most
upstream and most downstream significant SNP. In GWAS and
replication studies of these GWAS, the critical region was
determined as described by Barrett et al. [14]. In brief: The
HapMap of the CEU population was used to define the set of
HapMap SNPs with an r2.0.5 to the reported SNP. The critical
region was delimited by the outer boundaries of the flanking
HapMap recombination hotspots that contained this set of SNPs.
If the outer SNPs in this set were residing within a recombination
hotspot, the adjacent HapMap hotspot was used to define the
boundary. Linkage disequilibrium (LD) data and recombination
hotspot positions were retrieved from the HapMap Genome
Browser, release 24 (www.hapmap.org) [109]. Coordinates for the
SNP positions and recombination hotspots were in NCBI build 35
coordinates [110]. To map these regions onto the gene locations in
MEROPS, we converted NCBI 35 coordinates to NCBI 36
coordinates using the Batch Coordinate Conversion (LiftOver)
utility provided by UCSC (http://genome.ucsc.edu/cgi-bin/
hgLiftOver).
The methodological quality of included studies was assessed
referring to three major types of bias occurring in genetic studies
[108]: bias in phenotype definition, bias in genotyping, and
population stratification. Studies were classified to have adequate
protection against bias in phenotype definition if clear, widely
agreed definitions were used, efforts for retrospective harmoniza-
tion were undertaken, or a prospective standardization of
phenotypes was performed. Protection against bias in genotype
definition was deemed to be adequate if appropriate quality
control checks were reported. The effects of population stratifica-
tion were deemed to be adequately avoided if same descent groups
were included, statistical adjustment for reported descent was
described, a family-based design was used, or genomic control was
performed [108].
Data synthesis
Each gene and critical region extracted from the genetic studies
was specifically located on the human genome using the mega-
base location of upstream and downstream boundaries as
described above. For example, in a genome-wide linkage study
[71], a critical region associated with IBD was described to be
located at 1p32. We translated this genomic region into 51.29
mega base pairs (Mb) upstream boundary and 60.91 Mb
downstream boundaries. Then, we used a computer algorithm
to map all P/PI genes listed in the MEROPS database onto the
studied critical regions: for each P/PI gene, we determined
whether the location of the gene overlapped with any of the
extracted critical regions evaluated in the genetic studies. In view
of potential deficiencies in precision and resolution of source
databases and the possibility of regulatory upstream and
downstream regions located adjacent to the genes coding for the
P/PI, we broadened the width of the specified P/PI gene location
by 10 kilo base pairs for both the upstream and downstream
boundary. For example, matrix metallopeptidase-2 (MMP-2) was
defined by 54.07 Mb upstream and 54.10 Mb downstream
boundary; we widened this to 54.06 Mb upstream and
54.11 Mb downstream.
For each study type, we determined the proportion of positive
studies separately for CD and UC. The proportion was defined as
the number of studies positive on a P/PI gene divided by the total
number of studies found by the computer algorithm to assess
critical regions including the P/PI gene. For MMP2 in CD, for
example, none of the 5 GWAS was positive (proportion 0.0),
MMP2 was not investigated in replications of GWAS, neither in
candidate gene studies, but 6 of 7 candidate region studies were
positive (proportion 0.86), and 3 of 11 genome-wide linkage
studies (proportion 0.27). We pre-specified an overall ‘‘evidence
score’’ as primary outcome of our study. The evidence score took
into account both, the absolute number of positive studies, and the
proportion of positive studies among the total number of available
studies, as well as differences between study types in the accuracy
of genetic analyses:
ScoreP=PI~100|
X
all study types Cstudy type|Npositive
2

Ntotal
 
with ScoreP/PI being the evidence score, gall study types the sum
across all study types, Npositive the number of positive studies on a P/
PI gene, Ntotal the total number of studies found by the computer
algorithm to evaluate the P/PI gene, and Cstudy type a weighting
factor according to study type. Candidate gene sudies, GWAS and
replication studies of GWAS were considered more accurate than
candidate region and genome-wide linkage scans, therefore the
weighting factor was set at Cstudy type = 1.00 for GWAS, replication
of GWAS and candidate gene studies, Cstudy type = 0.50 for
candidate region studies, and Cstudy type= 0.33 for genome-wide
linkage scans. We ranked all P/PI genes according to this score, but
discarded P/PI genes with less than 2 positive studies or a score
#50; criteria for discarding were identical for CD and UC. An
evidence score of 50 will be reached, for example, if two out of four
candidate region studies were positive. Then, we derived test
statistics for observed versus expected uniform distributions of scores
using a signed test. As ‘‘positive controls’’ we used non-P/PI genes
with firmly established association with CD (CARD15 on chromo-
some 16q12.1 [Mb 49.28 to 49.32], ATG16L1 on chromosome
2q37.1 [Mb 233.82 to 233.87]) and both CD and UC (IL23R on
chromosome 1p31.3 [Mb 67.40 to 67.50]). If these positive controls
ranked high this would suggest our approach to be valid. Since
GWAS received major weight in the calculation of evidence scores,
we performed a sensitivity analysis recalculating ranks after
omission of GWAS. A second sensitivity analysis was performed
using an alternate weighting scheme for different study types, with
weighting factors set at Cstudy type = 1.00 for GWAS, replication of
GWAS and candidate gene studies, Cstudy type = 0.75 for candidate
region studies, and Cstudy type = 0.50 for genome-wide linkage scans.
Then, we used repeated random sampling of P/PI genes not
identified in GWAS to derive ‘‘negative controls’’ and compared
mean scores found for these negative controls with mean scores in
P/PI genes who met genome-wide significance in at least one
GWAS at p,561028. Lower mean scores in negative controls
would support the validity of our approach. Finally, we determined
whether top ranked P/PI genes met genome-wide significance
(p,561028) in the two most recent meta-analyses of GWAS in CD
and UC [76,77]. The data synthesis and mapping was performed
using GeneRank (University of Bern, Bern, Switzerland) developed
in Webspirit (2 mt software Ltd, Ulm, Germany) and Stata version
10.1 (College Station, Tex, USA).
Supporting Information
Figure S1 Chromosome plot of the number of studies
covering different genomic regions and corresponding
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numbers of positive studies, presented separately for
CD and UC. The total number of performed studies is shown in
grey, separately for CD (upper track) and UC (lower track), the
number of positive studies reporting a genetic association with CD
in blue (upper track) and the number of positive studies reporting a
genetic association with UC in red (lower track). Top ranked 20
CD and UC P/PI genes are specified in the figure in blue if
associated with CD, in red if associated with UC, in black if
associated with both phenotypes. Critical regions defined as before
were processed in 1 Mb bins with a perl script and the data was
visualized using UCSC Genome Graphs (http://genome.ucsc.
edu/cgi-bin/hgGenome).
(PDF)
Figure S2 ‘‘GeneRank’’ Sensitivity assay. Original ranks
of P/PI genes on the x-axis are plotted against ranks yielded after
omission of GWAS in sensitivity analyses on the y-axis for CD
(Panel A) and UC (Panel B).
(PDF)
Figure S3 Ranking of P/PI genes in CD and UC with
different weighting factors of types of genetic studies.
Ranks obtained for CD (panel A) and UC (panel B) applying the
original weighting factors set at Cstudy type = 1.00 for GWAS,
replication of GWAS and candidate gene studies, Cstudy type = 0.5
for candidate region studies, and Cstudy type = 0.33 for genome-wide
linkage scans (rank 1, x-axis) plotted against ranks obtained with an
alternate scheme using weighting factors set at Cstudy type =
1.00 for GWAS, replication of GWAS and candidate gene studies,
Cstudy type= 0.75 for candidate region studies and Cstudy type= 0.33
for genome-wide linkage scans (rank 2, y-axis).
(PDF)
Table S1 Assessment of the methodological quality of
included studies.
(XLS)
Table S2 Proteases and protease inhibitors with exact
genomic location extracted from the Merops database
(release 8.2).
(XLS)
Table S3 All proteases and protease inhibitors fulfilling
the pre-defined thresholds for Crohn’s disease (evidence
score .50 and at least 2 positive studies).
(DOC)
Table S4 Top ranked P/PI genes in CD mapping to loci
identified in the GWAS meta-analysis. Top ranked P/PI
genes in CD mapping to loci with genome-wide significance
(p,5*1028) identified in the GWAS meta-analysis by Franke et al.
(Nature Genetics, Dec 2010).
(XLSX)
Table S5 Top ranked P/PI genes in UC mapping to loci
identified in the GWAS meta-analysis. Top ranked P/PI
genes in UC mapping to loci with genome-wide significance
(p,5*1028) identified in the GWAS meta-analysis by Anderson et
al. (Nature Genetics, Feb 2011).
(XLSX)
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